Fairness opinions › Bankers
BroadOak Capital Partners: healthcare fairness opinions
1 opinions in healthcare transactions, 2025-2025 — 1 to a special committee. Each links to the filing and the full summary of analyses.
Opinions
1
2025-2025
Typical DCF discount rate
12.0%–16.0%
median of low / high · n=1
Terminal method
exit multiple 1
Median disclosed fee
$1.8M
n=1
Deals
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate |
|---|---|---|---|---|---|---|---|
| 2025-06-23 | Enzo Biochem | Battery Ventures | Diagnostics / Life Sciences | $37.0M | — | 1.35x | 12.0%–16.0% |
Segments: Diagnostics / Life Sciences (1)
3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.